|
Stenosis, which develops progressively over time, can be due to a number of issues.Additionally, there can be a number of potential known and unknown patient related contributing factors.Structural valve deterioration (svd), a common reason for bioprosthesis explant or reoperation, encompasses multiple failure modes, including calcific and non-calcific degeneration, dehiscence, cusp thickening or fibrosis, or a combination of these.Such failure modes, occurring singularly or concomitantly, may contribute to stenosis and/or regurgitation.Alternatively, nonstructural dysfunction (nsvd) may also play a role in the development of valvular stenosis.Stenosis is most commonly related to patient factors, and is not usually an indication of a device malfunction.The device was not returned for evaluation, as it remains implanted.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.
|
|
It was reported that a 23 mm pericardial aortic valve was disabled via a valve-in-valve procedure via the axillary artery after an implant duration of 6 years, 9 months due to severe stenosis.The patient presented with chf.A 23 mm transcatheter valve was implanted.The patient was discharged on pod #3.Per rep, physician believes surgical valve failed prematurely.
|
|
The most likely cause of the reported stenosis is patient factors, including coronary artery disease (cad), hyperlipidemia (hld), diabetes mellitus type ii (dm ii), and chronic kidney disease (ckd), and is not a result of a manufacturing non-conformance.The device history record (dhr) was reviewed and showed that this device met all manufacturing and sterilization specifications for product release prior to distribution.No issues were identified that would have impacted this event.Edwards will continue to review and monitor all events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|